OCTAVE study reveals vaccine responses in patients with impaired immune systems
Existing drug opens new possibilities for treating child leukemia
25 August 2021To reduce preeclampsia risk, study says take action before and between pregnancies
25 August 2021OCTAVE study reveals vaccine responses in patients with impaired immune systems
The OCTAVE study—a multi-center, UK-wide trial, led by the University of Glasgow and co-ordinated by the University of Birmingham’s Cancer Research UK Clinical Trials Unit—is evaluating the immune responses following COVID-19 vaccination in patients with immune-mediated inflammatory diseases such as cancer, inflammatory arthritis, diseases of the kidney or liver, or patients who are having a stem cell transplant.
